文献

J-GLOBAL ID：202002250766402486   整理番号：20A2440346

急性腎拒絶反応治療におけるドナー由来無細胞DNAアッセイの予後的価値:前向きコホート研究【JST・京大機械翻訳】

Prognostic value of the donor-derived cell-free DNA assay in acute renal rejection therapy: A prospective cohort study

著者 (57件)： Shen Jia (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Shen Jia (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Shen Jia (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Shen Jia (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Guo Luying (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Guo Luying (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Guo Luying (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Guo Luying (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Yan Pengpeng (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Yan Pengpeng (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Yan Pengpeng (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Yan Pengpeng (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Zhou Jingyi (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Zhou Jingyi (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Zhou Jingyi (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Zhou Jingyi (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Zhou Qin (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Zhou Qin (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Zhou Qin (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Zhou Qin (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Lei Wenhua (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Lei Wenhua (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Lei Wenhua (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Lei Wenhua (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Liu Haitao (AlloDx (Shanghai) biotech., Co., Ltd, Shanghai, China) ,  Liu Guangjun (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Liu Guangjun (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Liu Guangjun (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Liu Guangjun (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Lv Junhao (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Lv Junhao (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Lv Junhao (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Lv Junhao (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Liu Feng (AlloDx (Shanghai) biotech., Co., Ltd, Shanghai, China) ,  Huang Hongfeng (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Huang Hongfeng (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Huang Hongfeng (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Huang Hongfeng (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Dong Wenzhao (AlloDx (Shanghai) biotech., Co., Ltd, Shanghai, China) ,  Shu Liping (AlloDx (Shanghai) biotech., Co., Ltd, Shanghai, China) ,  Wang Huiping (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wang Huiping (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Wang Huiping (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Wang Huiping (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Wu Jianyong (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wu Jianyong (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Wu Jianyong (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Wu Jianyong (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Chen Jianghua (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Chen Jianghua (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Chen Jianghua (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Chen Jianghua (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Wang Rending (Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China) ,  Wang Rending (National Key Clinical Department of Kidney Diseases, Zhejiang, China) ,  Wang Rending (Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang, China) ,  Wang Rending (Zhejiang University Institute of Nephrology, Hangzhou, China) ,  Wang Rending (Organ Donation and Coordination Office, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
資料名： Clinical Transplantation  (Clinical Transplantation)
巻： 34  号： 10  ページ： e14053  発行年： 2020年 
JST資料番号： W3480A  ISSN： 0902-0063  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： ドナー由来無細胞DNA(dd-cfDNA)は同種移植片状態を監視するための有望なバイオマーカーである。しかし,dd-cfDNAがリアルタイム抗拒絶反応治療効果を反映するかどうかは不明である。著者らは,ABMRを有する5例,IA型またはIB型拒絶を伴う12例,およびIIA型またはIIB型拒絶の11例を含む急性腎拒絶の28例の患者を前向きに募集し,ヒト一塩基多型(SNP)遺伝子座捕獲ハイブリダイゼーションを用いて末梢血におけるIIA型またはIIB型拒絶のdd-cfDNAレベルを測定した。dd-cfDNA(dd-cfDNA%)のパーセンテージは,抗拒絶療法の後,2.566±0.549%から0.773±0.116%(P<0.001)まで有意に減少した。dd-cfDNA%は,毎日のメチルプレドニゾロン注射で3日間経過の間,着実に減少したが,dd-cfDNA%の有意差は,抗拒絶療法の終わりと2週後に観察されなかった。dd-cfDNA%(Δdd-cfDNA%)の変化は,治療後1か月(ρ=2.570,P=0.022),3か月(ρ=3.210,P=0.027)および6か月(ρ=2.860,P=0.019)で推定糸球体濾過率と正相関を示した。したがって,dd-cfDNAアッセイは治療転帰と同種移植片回復における予後能力を示した。しかし,その能力は拒絶のタイプに関係なくメチルプレドニゾロンによって阻害される。さらに,試験のための周波数間隔の再評価が必要である。Copyright 2020 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： ヒト ,  *拒絶反応 ,  捕獲 ,  *予後 ,  順相 ,  バイオマーカー ,  末梢血 ,  一塩基多型 ,  前向きコホート研究 ,  *ドナー【臓器移植】 ,  ステロイド ,  ジエン ,  グルココルチコイド ,  エノン ,  脂環式アルコール ,  脂環式ケトン ,  ジケトン ,  ヒドロキシケトン ,  ポリオール
準シソーラス用語： 同種移植片 ,  *無細胞DNA , 【Automatic Indexing@JST】

著者キーワード (4件)： 急性拒絶反応 ,  ドナー由来無細胞DNA ,  腎臓移植 ,  予後

分類 (5件)： 移植免疫  (ED03020E) ,  消化器疾患の外科療法  (GH05030R) ,  泌尿生殖器疾患の外科療法  (GM05030G) ,  遺伝的変異  (EC01030Y) ,  分子遺伝学一般  (EC02010J)

物質索引 (1件)： メチルプレドニゾロン

タイトルに関連する用語 (9件)： 腎 ,  拒絶反応 ,  治療 ,  ドナー ,  無細胞DNA ,  アッセイ ,  予後 ,  価値 ,  前向きコホート研究